Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Finance Watch: VC Tally Hits $14.5bn For 2018, Beating 2017 With A Quarter Left To Go

Executive Summary

US VC investment in biopharma totaled $14.5bn in the first three quarters of 2018, exceeding the full-year 2017 sum of $11.9bn. UK biotech cash also is rising, benefitting new companies like Sitryx.
Advertisement

Related Content

Finance Watch: With The Year's Biggest IPO, CFO Says Allogene Is Ready To Go 'Full Throttle'
Gotham Therapeutics Raises $54M Series A To Target RNA-Modifying Proteins
GSK-Backed Sitryx Launches With Six Immunometabolism Eggs In Its Basket
IPO Update: Returns Sag As Seven More Biopharmas Go Public In September
Momenta Refocuses On Three Novel Autoimmune Drugs In Transition To More Traditional Biotech
Realm Reaches End of The Road And Seeks Buyer
Finance Watch: 2018 Biopharma VC Investment Could Beat 2017 One Quarter Ahead Of Schedule
Accera Posts Phase III Alzheimer's Failure, But Moves Ahead With New Formulation
VC Roundup: Annexon, Mersana Benefit As Investors Favor Private Over Public Biotechs
Recent Financings Of Private Companies, May 2013

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC124011

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel